{"id":14315,"date":"2024-11-23T13:26:49","date_gmt":"2024-11-23T05:26:49","guid":{"rendered":"https:\/\/flcube.com\/?p=14315"},"modified":"2024-11-23T13:34:28","modified_gmt":"2024-11-23T05:34:28","slug":"chinese-biopharma-bio-bank-corp-aims-for-hkex-ipo-focused-on-pdgf-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14315","title":{"rendered":"Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies"},"content":{"rendered":"\n

On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China, has resubmitted its application for listing on the Hong Kong Stock Exchange (HKEX). The company is advised by joint sponsors Hua Tai International and CITIC Securities.<\/p>\n\n\n\n

Company Background and Therapeutic Focus<\/strong>
Founded in 2012, Bio-Bank Corp. is dedicated to developing protein-based therapies for indications with significant medical needs and market opportunities. The company’s primary focus is on the discovery, development, and commercialization of therapies for wound healing, specifically targeting Platelet-Derived Growth Factor (PDGF) drugs.<\/p>\n\n\n\n

PDGF Drugs Development and Market Potential<\/strong>
PDGF is a growth factor secreted by platelets post-injury, stimulating cell proliferation and angiogenesis. Bio-Bank Corp.’s core products, Pro-101-1 and Pro-101-2, are recombinant human Platelet-Derived Growth Factor-BB (rhPDGF-BB) drugs. PDGF-BB is one of the five dimeric subtypes of PDGF, with rhPDGF-BB being its clinical application form. According to a Frost & Sullivan report, Pro-101-1 is the PDGF candidate with the most advanced clinical development progress in China for the treatment of burns and scalds. Additionally, Bio-Bank Corp. is positioned to be a leading biopharmaceutical company in China for the commercialization of PDGF drugs for the treatment of diabetic foot ulcers, also known as “diabetic mellitus foot,DMF<\/em>.”<\/p>\n\n\n\n

Fundraising and Valuation<\/strong>
Between 2021 and 2023, Bio-Bank Corp. completed three rounds of financing, raising over 4 billion yuan, with a valuation of 3.3 billion yuan post-Series B financing. <\/p>\n\n\n\n

Financial Performance<\/strong>
Financially, Bio-Bank Corp. reported total comprehensive losses of 85.953 million yuan, 105 million yuan, and 164 million yuan for the years 2022, 2023, and the first nine months of 2024, respectively.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China,…<\/p>\n","protected":false},"author":1,"featured_media":14318,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[2284,2285,20,72],"class_list":["post-14315","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-bk-corporation","tag-bio-bank-corp","tag-finance","tag-ipo"],"yoast_head":"\nChinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China, has resubmitted its application for listing on the Hong Kong Stock Exchange (HKEX). The company is advised by joint sponsors Hua Tai International and CITIC Securities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14315\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14315\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-23T05:26:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-23T05:34:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/ef3fe9396186a61dc312a20b7f671208.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"525\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14315#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14315\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies\",\"datePublished\":\"2024-11-23T05:26:49+00:00\",\"dateModified\":\"2024-11-23T05:34:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14315\"},\"wordCount\":274,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14315#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/ef3fe9396186a61dc312a20b7f671208.png\",\"keywords\":[\"B&K Corporation\",\"Bio-Bank Corp\",\"Finance\",\"IPO\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14315#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14315\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14315\",\"name\":\"Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14315#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14315#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/ef3fe9396186a61dc312a20b7f671208.png\",\"datePublished\":\"2024-11-23T05:26:49+00:00\",\"dateModified\":\"2024-11-23T05:34:28+00:00\",\"description\":\"On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China, has resubmitted its application for listing on the Hong Kong Stock Exchange (HKEX). The company is advised by joint sponsors Hua Tai International and CITIC Securities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14315#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14315\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14315#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/ef3fe9396186a61dc312a20b7f671208.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/ef3fe9396186a61dc312a20b7f671208.png\",\"width\":1080,\"height\":525,\"caption\":\"Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14315#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies - Insight, China's Pharmaceutical Industry","description":"On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China, has resubmitted its application for listing on the Hong Kong Stock Exchange (HKEX). The company is advised by joint sponsors Hua Tai International and CITIC Securities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14315","og_locale":"en_US","og_type":"article","og_title":"Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14315","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-23T05:26:49+00:00","article_modified_time":"2024-11-23T05:34:28+00:00","og_image":[{"width":1080,"height":525,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/ef3fe9396186a61dc312a20b7f671208.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14315#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14315"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies","datePublished":"2024-11-23T05:26:49+00:00","dateModified":"2024-11-23T05:34:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14315"},"wordCount":274,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=14315#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/ef3fe9396186a61dc312a20b7f671208.png","keywords":["B&K Corporation","Bio-Bank Corp","Finance","IPO"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14315#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14315","url":"https:\/\/flcube.com\/?p=14315","name":"Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=14315#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=14315#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/ef3fe9396186a61dc312a20b7f671208.png","datePublished":"2024-11-23T05:26:49+00:00","dateModified":"2024-11-23T05:34:28+00:00","description":"On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China, has resubmitted its application for listing on the Hong Kong Stock Exchange (HKEX). The company is advised by joint sponsors Hua Tai International and CITIC Securities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14315#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14315"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=14315#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/ef3fe9396186a61dc312a20b7f671208.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/ef3fe9396186a61dc312a20b7f671208.png","width":1080,"height":525,"caption":"Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14315#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/ef3fe9396186a61dc312a20b7f671208.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14315"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14315\/revisions"}],"predecessor-version":[{"id":14320,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14315\/revisions\/14320"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/14318"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}